Dublin, Ireland - November 26, 2019 - Cosmo Pharmaceuticals N.V. (SIX: COPN) today announced that Luigi Moro, its Chief Scientific Officer, is retiring and that Roberto Camerini MD will assume his responsibilities as of January 1, 2020.
Luigi Moro joined Cosmo in 1999 after a long career in drug development in Farmitalia Carlo Erba, Recordati and Poli Industria Chimica. He led the development of all approved Cosmo products to date, namely Lialda, Uceris, Eleview and Aemcolo; and he also led the development of all Cassiopea products to date. Mr. Moro will continue making his services available as a consultant to Cosmo and will continue being the CSO of Cassiopea.
Roberto Camerini MD joined Cosmo in December 2018. He was formerly Director of Pre-Clinical and Clinical Research and Development at Alfa Wassermann S.p.A. from 2015 to 2018, and Head of Corporate Clinical Research at Sigma Tau S.p.A. Previously he worked for Serono and Abbot.
Mauro Ajani, Executive Chairman of Cosmo said: "I recruited Luigi when we were but a handful of people. His expertise contributed in an essential fashion to the transformation of Cosmo from a small contract drug manufacturer to a listed specialty pharma company and I will be forever thankful for that. It is great that he is willing to continue making his experience available to the Company. We believe we have found in Roberto Camerini the right successor to lead our product development".